Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Chen‐Song Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4652-987X; OpenAlex author ID A5091579467. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 10

  1. Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH-Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocar… Co-author DOI 10.1002/adhm.202503694↗
  2. The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chem… Co-author DOI 10.1186/s12885-026-16353-z↗
  3. Remote robot-assisted pancreatoduodenectomy for one patient with pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/hbsn-2025-1-913↗
  4. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202406714↗
  5. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2022.11.004↗
  6. HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.07.016↗
  7. Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.201902926↗
  8. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1039/d0nr03138k↗
  9. The C/EBPβ-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1. Co-author DOI 10.1016/j.canlet.2018.02.020↗
  10. WAVE3 promotes proliferation, migration and invasion via the AKT pathway in pancreatic cancer. First author DOI 10.3892/ijo.2018.4421↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xi‐Tai Huang · 7 shared papers, 2018–2026 · strength 1.22
  2. Xiao-Yu Yin · 5 shared papers, 2018–2026 · strength 1.06
  3. Jie‐Qin Wang · 5 shared papers, 2020–2026 · strength 0.84
  4. Xiaoyu Yin · 5 shared papers, 2018–2026 · strength 0.76
  5. Yin-Hao Shi · 2 shared papers, 2023–2024 · strength 0.35
  6. Ying‐Qin Zhu · 2 shared papers, 2023–2024 · strength 0.35
  7. Zhide Liu · 2 shared papers, 2023–2024 · strength 0.35
  8. Wei Zhao · 3 shared papers, 2018–2021 · strength 0.33
  9. Xin Zhang · 1 shared paper, 2026 · strength 0.32
  10. Xiao‐Xu Zhu · 2 shared papers, 2018–2021 · strength 0.23
  11. Mingjian Ma · 1 shared paper, 2024 · strength 0.18
  12. Yue Huang · 1 shared paper, 2024 · strength 0.18
  13. Qi Liu · 1 shared paper, 2023 · strength 0.16
  14. Liying Wang · 1 shared paper, 2020 · strength 0.10
  15. Chaoxu Zheng · 1 shared paper, 2018 · strength 0.08
  16. Shaobin Huang · 1 shared paper, 2018 · strength 0.08
  17. Qian Wang · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.